We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y
Read MoreHide Full Article
Key Takeaways
ANGO's Q1 adjusted loss narrowed to 4 cents per share, beating estimates by 60%, as revenues rose 6.9%.
Med Tech revenues climbed 13.2%, driven by strong Auryon, AlphaVac and NanoKnife sales growth.
ANGO's gross margin expanded 410 basis points to 59.4%, while operating loss narrowed to $7.3 million.
AngioDynamics, Inc. (ANGO - Free Report) reported an adjusted loss per share of 4 cents for first-quarter fiscal 2027, narrower than the year-ago quarter’s adjusted loss of 10 cents. The figure also beat the consensus estimate by 60%.
Revenues totaled $80.9 million, up 6.9% year over year, in line with the Zacks Consensus Estimate. Growth was primarily driven by strong Med Tech performance, particularly Auryon, AlphaVac and NanoKnife. The company also recorded a substantial improvement in gross margin.
ANGO's Q1 Revenue Performance
AngioDynamics continued to benefit from its strategic shift toward higher-growth Med Tech products. The business contributed approximately 49% of total revenues compared with 47% in the year-ago period.
Management expects Med Tech to account for a majority of total revenues during fiscal 2027. The company recorded its eighth consecutive quarter of double-digit Med Tech revenue growth and positive adjusted EBITDA.
However, shares of this company lost more than 20% during yesterday’s trading.
AngioDynamics’ Geographical Analysis
In the quarter under review, U.S. net revenues totaled $71.1 million, reflecting an improvement of 6.9% from the year-ago quarter's $66.5 million.
International revenues amounted to $9.8 million, up 6.4% from the prior-year period's $9.3 million. Growing international adoption of the Auryon platform, following its CE Mark approval, supported the company's expansion efforts.
ANGO’s Q1 Segmental Analysis
AngioDynamics derives revenues from two businesses — Med Tech and Med Device.
Med Tech
Med Tech revenues totaled $39.9 million, increasing 13.2% from the prior-year quarter.
Auryon sales reached $18.9 million, reflecting 14.7% growth and marking the platform's 21st consecutive quarter of double-digit year-over-year growth. Increasing adoption across hospitals and office-based laboratories supported performance.
Mechanical Thrombectomy revenues increased 6.7% to $12 million. AlphaVac revenues climbed 37.4% to $4.5 million, while AngioVac revenues declined 5.9% to $7.5 million. Sequentially, AlphaVac and AngioVac revenues grew 6.4% and 9.1%, respectively.
NanoKnife revenues jumped 29% to $8.3 million, supported by 24.1% growth in probe sales and 53.5% growth in capital sales. Management highlighted record prostate procedure volumes, reflecting increasing physician adoption.
Med Device
Med Device revenues reached $41 million, up 1.4% from $40.4 million in the comparable period.
Management continues to view this business as a consistent source of cash generation and profitability, supporting investments in higher-growth Med Tech platforms.
AngioDynamics, Inc. Price, Consensus and EPS Surprise
Gross profit increased 14.8% year over year to $48 million. Gross margin expanded 410 basis points to 59.4%, primarily benefiting from favorable pricing and a greater contribution from higher-margin Med Tech products. Excluding tariff refunds, gross margin was 57.8%.
Research and development expenses increased 24.3% year over year to $8 million. Sales and marketing expenses rose 6.6% year over year to $30 million, while general and administrative expenses declined 0.7% to $12.5 million.
Total operating expenses increased 5.4% year over year to $55.3 million. However, operating loss narrowed year over year to $7.3 million from $10.7 million.
ANGO’s Cash Position
AngioDynamics exited the first quarter of fiscal 2027 with cash of $33.9 million compared with $53.9 million at the fiscal 2026 end.
The company ended the quarter with no debt on its balance sheet.
Net cash used in operating activities totaled $15.3 million compared with $15.9 million in the prior-year quarter. Management expects positive operating cash flow for the full fiscal year, with the fiscal fourth quarter likely to generate the strongest cash inflows.
AngioDynamics’ FY27 Guidance
AngioDynamics reiterated its fiscal 2027 revenue guidance of $336-$341 million, representing projected growth of 5-6.5% year over year. The Zacks Consensus Estimate is currently pegged at $338.5 million.
Med Tech revenue growth is expected between 12% and 15%, while Med Device revenues are projected to remain flat.
Management continues to expect gross margin of 54-55% and adjusted EBITDA between $13 million and $16 million. Adjusted loss per share is anticipated between 29 cents and 24 cents.
The company expects tariff-related impacts to remain broadly comparable to fiscal 2026, excluding refunds.
The adjusted loss per share is projected to be between 29 cents and 24 cents. The Zacks Consensus Estimate is currently pegged at a loss of 26 cents per share.
ANGO's Clinical Progress and Leadership Transition
AngioDynamics' expanding clinical portfolio strengthens its long-term Med Tech growth opportunities. The FDA's Investigational Device Exemption approval for the RELIEF study represents a notable development for NanoKnife. The study will evaluate the technology for treating benign prostatic hyperplasia, potentially expanding its applications beyond oncology.
NanoKnife reimbursement progress, including a favorable Medicare Administrative Contractor coverage decision, could support wider adoption. Meanwhile, ongoing AlphaReturn and AngioVac clinical studies, alongside Auryon's AMBITION BTK study, offer additional opportunities for expanding the company's addressable markets.
The company also announced that Eric Honroth will succeed Jim Clemmer as president and CEO, effective Nov. 2, 2026. Honroth's extensive medical technology leadership experience could support the company's next phase of growth as it continues executing the Med Tech-focused strategy.
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. West Pharmaceutical’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.
View the Zacks #1 Rank List
Image: Zacks
ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y
Key Takeaways
AngioDynamics, Inc. (ANGO - Free Report) reported an adjusted loss per share of 4 cents for first-quarter fiscal 2027, narrower than the year-ago quarter’s adjusted loss of 10 cents. The figure also beat the consensus estimate by 60%.
Revenues totaled $80.9 million, up 6.9% year over year, in line with the Zacks Consensus Estimate. Growth was primarily driven by strong Med Tech performance, particularly Auryon, AlphaVac and NanoKnife. The company also recorded a substantial improvement in gross margin.
ANGO's Q1 Revenue Performance
AngioDynamics continued to benefit from its strategic shift toward higher-growth Med Tech products. The business contributed approximately 49% of total revenues compared with 47% in the year-ago period.
Management expects Med Tech to account for a majority of total revenues during fiscal 2027. The company recorded its eighth consecutive quarter of double-digit Med Tech revenue growth and positive adjusted EBITDA.
However, shares of this company lost more than 20% during yesterday’s trading.
AngioDynamics’ Geographical Analysis
In the quarter under review, U.S. net revenues totaled $71.1 million, reflecting an improvement of 6.9% from the year-ago quarter's $66.5 million.
International revenues amounted to $9.8 million, up 6.4% from the prior-year period's $9.3 million. Growing international adoption of the Auryon platform, following its CE Mark approval, supported the company's expansion efforts.
ANGO’s Q1 Segmental Analysis
AngioDynamics derives revenues from two businesses — Med Tech and Med Device.
Med Tech
Med Tech revenues totaled $39.9 million, increasing 13.2% from the prior-year quarter.
Auryon sales reached $18.9 million, reflecting 14.7% growth and marking the platform's 21st consecutive quarter of double-digit year-over-year growth. Increasing adoption across hospitals and office-based laboratories supported performance.
Mechanical Thrombectomy revenues increased 6.7% to $12 million. AlphaVac revenues climbed 37.4% to $4.5 million, while AngioVac revenues declined 5.9% to $7.5 million. Sequentially, AlphaVac and AngioVac revenues grew 6.4% and 9.1%, respectively.
NanoKnife revenues jumped 29% to $8.3 million, supported by 24.1% growth in probe sales and 53.5% growth in capital sales. Management highlighted record prostate procedure volumes, reflecting increasing physician adoption.
Med Device
Med Device revenues reached $41 million, up 1.4% from $40.4 million in the comparable period.
Management continues to view this business as a consistent source of cash generation and profitability, supporting investments in higher-growth Med Tech platforms.
AngioDynamics, Inc. Price, Consensus and EPS Surprise
AngioDynamics, Inc. price-consensus-eps-surprise-chart | AngioDynamics, Inc. Quote
AngioDynamics’ Margin and Cost Trends
Gross profit increased 14.8% year over year to $48 million. Gross margin expanded 410 basis points to 59.4%, primarily benefiting from favorable pricing and a greater contribution from higher-margin Med Tech products. Excluding tariff refunds, gross margin was 57.8%.
Research and development expenses increased 24.3% year over year to $8 million. Sales and marketing expenses rose 6.6% year over year to $30 million, while general and administrative expenses declined 0.7% to $12.5 million.
Total operating expenses increased 5.4% year over year to $55.3 million. However, operating loss narrowed year over year to $7.3 million from $10.7 million.
ANGO’s Cash Position
AngioDynamics exited the first quarter of fiscal 2027 with cash of $33.9 million compared with $53.9 million at the fiscal 2026 end.
The company ended the quarter with no debt on its balance sheet.
Net cash used in operating activities totaled $15.3 million compared with $15.9 million in the prior-year quarter. Management expects positive operating cash flow for the full fiscal year, with the fiscal fourth quarter likely to generate the strongest cash inflows.
AngioDynamics’ FY27 Guidance
AngioDynamics reiterated its fiscal 2027 revenue guidance of $336-$341 million, representing projected growth of 5-6.5% year over year. The Zacks Consensus Estimate is currently pegged at $338.5 million.
Med Tech revenue growth is expected between 12% and 15%, while Med Device revenues are projected to remain flat.
Management continues to expect gross margin of 54-55% and adjusted EBITDA between $13 million and $16 million. Adjusted loss per share is anticipated between 29 cents and 24 cents.
The company expects tariff-related impacts to remain broadly comparable to fiscal 2026, excluding refunds.
The adjusted loss per share is projected to be between 29 cents and 24 cents. The Zacks Consensus Estimate is currently pegged at a loss of 26 cents per share.
AngioDynamics, Inc. Price
AngioDynamics, Inc. price | AngioDynamics, Inc. Quote
ANGO's Clinical Progress and Leadership Transition
AngioDynamics' expanding clinical portfolio strengthens its long-term Med Tech growth opportunities. The FDA's Investigational Device Exemption approval for the RELIEF study represents a notable development for NanoKnife. The study will evaluate the technology for treating benign prostatic hyperplasia, potentially expanding its applications beyond oncology.
NanoKnife reimbursement progress, including a favorable Medicare Administrative Contractor coverage decision, could support wider adoption. Meanwhile, ongoing AlphaReturn and AngioVac clinical studies, alongside Auryon's AMBITION BTK study, offer additional opportunities for expanding the company's addressable markets.
The company also announced that Eric Honroth will succeed Jim Clemmer as president and CEO, effective Nov. 2, 2026. Honroth's extensive medical technology leadership experience could support the company's next phase of growth as it continues executing the Med Tech-focused strategy.
AngioDynamics’ Zacks Rank & Key Picks
ANGO currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. West Pharmaceutical’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.